

CERVICAL CANCER SCREENING

VOLUME 18

This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Cancer-Preventive Interventions, which met remotely, 12–16 October 2020

LYON, FRANCE - 2022

IARC HANDBOOKS OF
CANCER PREVENTION

CONTENTS

NOTE TO THE READER	1
LIST OF PARTICIPANTS	3
PREAMBLE – SECONDARY PREVENTION	9
A. GENERAL PRINCIPLES AND PROCEDURES	9
1. Background.....	9
2. Objectives, scope, and definitions.....	10
3. Identification and selection of interventions and outcomes for review.....	12
4. The Working Group and other meeting participants.....	13
5. Development of a volume of the <i>IARC Handbooks</i>	16
6. Overview of the scientific review and evaluation process.....	17
7. Responsibilities of the Working Group.....	19
B. SCIENTIFIC REVIEW AND EVALUATION	20
1. Definitions.....	20
2. Characterization of the disease.....	22
3. Screening methods.....	22
4. Current global screening practices.....	23
5. Epidemiological studies of each screening method.....	23
6. Summary of data reported.....	34
7. Evaluation and rationale.....	34
References.....	37
GENERAL REMARKS	39
LIST OF ABBREVIATIONS	45
GLOSSARY	49
1. CERVICAL CANCER	53
1.1 Global cervical cancer burden.....	53
1.1.1 Incidence.....	53
1.1.2 Mortality.....	53
1.1.3 Trends in incidence.....	57
1.1.4 Lifetime risk of cervical cancer.....	60
1.1.5 Survival.....	60

1.1.6	Prevalence of HPV infection in women.....	62
1.1.7	Projections of global burden	63
1.2	Cervical neoplasia	64
1.2.1	Biology of HPV and of the cervix relevant to carcinogenesis and screening.....	64
1.2.2	Transmission and natural history of HPV infection and multistage cervical carcinogenesis.....	69
1.2.3	Terminology for pathological classification	74
1.2.4	Stage at diagnosis and survival.....	77
1.2.5	Treatment of cervical cancer and of precancerous lesions.....	78
	References.....	88
2.	CERVICAL CANCER SCREENING PROGRAMMES	97
2.1	Introduction	97
2.2	Availability and use of cervical cancer screening worldwide.....	98
2.2.1	WHO African Region.....	98
2.2.2	WHO Eastern Mediterranean Region.....	102
2.2.3	WHO European Region.....	106
2.2.4	WHO Region of the Americas: North America	114
2.2.5	WHO Region of the Americas: Latin America and the Caribbean.....	119
2.2.6	WHO South-East Asia Region	124
2.2.7	WHO Western Pacific Region	127
2.3	Quality assurance of screening programmes.....	132
2.3.1	Description and role of quality assurance in screening programmes.....	132
2.3.2	Examples of quality assurance within screening programmes.....	133
	References.....	135
3.	PARTICIPATION IN SCREENING FOR CERVICAL CANCER.....	153
3.1	Negative and positive determinants of participation	153
3.1.1	Health policy determinants.....	153
3.1.2	Structural determinants	155
3.1.3	Intermediate determinants at the individual level.....	157
3.1.4	Intermediate determinants at the programme or service organization level	158
3.1.5	Intermediate determinants at the health provider level.....	159
3.1.6	Informed decision-making	160
3.2	Interventions to increase screening participation.....	161
3.2.1	Interventions to increase participation in cytology-based screening	161
3.2.2	Interventions to increase participation in screening by HPV testing.....	169
	References.....	180
4.	PREVENTIVE AND ADVERSE EFFECTS OF CERVICAL CANCER SCREENING.....	187
4.1	Methodological issues.....	187
4.1.1	Considerations about beneficial effects of cervical screening	187
4.1.2	Considerations about harms of cervical screening.....	192
	References.....	195

4.2	Screening by visual inspection.....	200
4.2.1	Visual inspection techniques	200
4.2.2	Beneficial effects of screening using VIA.....	203
4.2.3	Harms of screening using VIA	206
	References.....	208
4.3	Cytological methods	211
4.3.1	Technical descriptions	211
4.3.2	Beneficial effects of screening using conventional cytology	221
4.3.3	Beneficial effects of screening using LBC	236
4.3.4	Cytology based on Romanowsky–Giemsa staining.....	249
4.3.5	Harms of cytological techniques.....	254
	References.....	261
4.4	HPV testing.....	275
4.4.1	Technical descriptions	275
4.4.2	Comparison of HPV DNA testing versus cytology	279
4.4.3	Comparison of HPV DNA testing versus VIA.....	296
4.4.4	Comparison of HPV DNA testing alone versus co-testing	309
4.4.5	HPV testing on self-collected versus clinician-collected samples	320
4.4.6	Comparison of HPV RNA testing versus HPV DNA testing	324
4.4.7	Triage of women with a positive primary HPV screening test result.....	328
4.4.8	Harms of HPV testing.....	333
	References.....	342
4.5	Colposcopy.....	357
4.5.1	Technical description of a colposcopic examination	357
4.5.2	Accuracy of colposcopy in cytology-based screening	361
4.5.3	Colposcopy in HPV-based screening	362
4.5.4	Random biopsies for diagnosis of CIN2+.....	363
4.5.5	Risk-based colposcopy practice	364
4.5.6	Harmful effects of colposcopy.....	365
	References.....	368
4.6	Emerging technologies.....	373
4.6.1	Emerging technologies using artificial intelligence.....	374
4.6.2	Emerging molecular technologies	379
	References.....	381
5.	SCREEN-AND-TREAT APPROACH AND WOMEN AT DIFFERENTIAL RISK	385
5.1	Screen-and-treat approach.....	385
5.1.1	Rationale for screen-and-treat strategies	385
5.1.2	Screening and triage modalities in screen-and-treat programmes.....	386
5.1.3	Treatment modalities in screen-and-treat programmes.....	387
5.1.4	Evaluation of screen-and-treat strategies.....	388
5.2	Screening of women at differential risk	393
5.2.1	Screening of women living with HIV.....	393
5.2.2	Screening of older women	401
5.2.3	Screening of women with a personal history of precancerous lesions.....	405
5.2.4	Screening of HPV vaccinated populations	415
	References.....	420

6. SUMMARY	431
6.1 Cervical cancer	431
6.1.1 Cervical cancer burden	431
6.1.2 Cervical neoplasia	431
6.2 Cervical cancer screening programmes	433
6.2.1 WHO African Region	433
6.2.2 WHO Eastern Mediterranean Region	433
6.2.3 WHO European Region	434
6.2.4 WHO Region of the Americas: North America	434
6.2.5 WHO Region of the Americas: Latin America and the Caribbean	434
6.2.6 WHO South-East Asia Region	434
6.2.7 WHO Western Pacific Region	435
6.2.8 Quality assurance of screening programmes	435
6.3 Participation in screening for cervical cancer	435
6.4 Preventive and adverse effects of cervical cancer screening methods	436
6.4.1 Visual screening methods	436
6.4.2 Cytological methods	437
6.4.3 HPV testing	439
6.4.4 Colposcopy	443
6.4.5 Emerging technologies	443
6.5 Screen-and-treat approach and women at differential risk	444
6.5.1 Screen-and-treat approach	444
6.5.2 Screening of women at differential risk	445
7. EVALUATIONS AND COMPARISON STATEMENTS	447
7.1 Visual inspection with acetic acid	447
7.2 Conventional cytology	448
7.3 Liquid-based cytology	449
7.4 HPV nucleic acid testing	450
7.5 Cytology based on Romanowsky–Giemsa staining	451
7.6 HPV DNA testing versus VIA	451
7.7 HPV DNA testing versus cytology	451
7.8 HPV DNA testing alone versus co-testing	452
7.9 Considerations on related issues	452
7.9.1 Triage	452
7.9.2 Self-sampling	453
7.9.3 Screen-and-treat strategies	453
7.9.4 Interventions to increase participation in screening	453
ANNEX 1. Supplementary material for Section 4.4.7 Triage of women with a positive primary HPV screening test result	455